Literature DB >> 19544435

mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis.

Heng Liang Tan1, Wey Jia Fong, Eng Hin Lee, Miranda Yap, Andre Choo.   

Abstract

The monoclonal antibody mAb 84, which binds to podocalyxin-like protein-1 (PODXL) on human embryonic stem cells (hESCs), was previously reported to bind and kill undifferentiated cells in in vitro and in vivo assays. In this study, we investigate the mechanism responsible for mAb 84-induced hESCs cytotoxicity. Apoptosis was likely not the cause of mAb 84-mediated cell death because no elevation of caspase activities or increased DNA fragmentation was observed in hESCs following incubation with mAb 84. Instead, it was preceded by cell aggregation and damage to cell membranes, resulting in the uptake of propidium iodide, and the leakage of intracellular sodium ions. Furthermore, examination of the cell surface by scanning electron microscopy revealed the presence of pores on the cell surface of mAb 84-treated cells, which was absent from the isotype control. This mechanism of cell death resembles that described for oncosis, a form of cell death resulting from membrane damage. Additional data suggest that the binding of mAb 84 to hESCs initiates a sequence of events prior to membrane damage, consistent with oncosis. Degradation of actin-associated proteins, namely, alpha-actinin, paxillin, and talin, was observed. The perturbation of these actin-associated proteins consequently permits the aggregation of PODXL, thus leading to the formation of pores. To our knowledge, this is the first report of oncotic cell death with hESCs as a model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544435     DOI: 10.1002/stem.109

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  40 in total

1.  Selective removal of undifferentiated embryonic stem cells from differentiation cultures through HSV1 thymidine kinase and ganciclovir treatment.

Authors:  Ortwin Naujok; Joanna Kaldrack; Terbish Taivankhuu; Anne Jörns; Sigurd Lenzen
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

Review 2.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

Review 3.  Advances in cell culture: anchorage dependence.

Authors:  Otto-Wilhelm Merten
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

Review 4.  The quest of cell surface markers for stem cell therapy.

Authors:  Anna Meyfour; Sara Pahlavan; Mehdi Mirzaei; Jeroen Krijgsveld; Hossein Baharvand; Ghasem Hosseini Salekdeh
Journal:  Cell Mol Life Sci       Date:  2020-07-24       Impact factor: 9.261

5.  Liquid formulations for stabilizing IgMs during physical stress and long-term storage.

Authors:  Monika Mueller; Maybelle Q T Loh; Rupert Tscheliessnig; Doris H Y Tee; Eddy Tan; Muriel Bardor; Alois Jungbauer
Journal:  Pharm Res       Date:  2012-11-10       Impact factor: 4.200

6.  Chemical ablation of tumor-initiating human pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Protoc       Date:  2014-02-27       Impact factor: 13.491

7.  Stem cell bioprocess engineering towards cGMP production and clinical applications.

Authors:  Sébastien Sart; Yves-Jacques Schneider; Yan Li; Spiros N Agathos
Journal:  Cytotechnology       Date:  2014-02-06       Impact factor: 2.058

8.  A Cytotoxic Antibody Recognizing Lacto-N-fucopentaose I (LNFP I) on Human Induced Pluripotent Stem (hiPS) Cells.

Authors:  Shogo Matsumoto; Hiromi Nakao; Keiko Kawabe; Motohiro Nonaka; Hidenao Toyoda; Yuto Takishima; Kenji Kawabata; Tomoko Yamaguchi; Miho K Furue; Takao Taki; Takeshi Okumura; Yuzo Yamazaki; Shuuichi Nakaya; Nobuko Kawasaki; Toshisuke Kawasaki
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

Review 9.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

10.  Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy.

Authors:  Saranya P Wyles; Satsuki Yamada; Saji Oommen; Joseph J Maleszewski; Rosanna Beraldi; Almudena Martinez-Fernandez; Andre Terzic; Timothy J Nelson
Journal:  Stem Cells Dev       Date:  2014-08-21       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.